High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate

@article{Chidakel2006HighPO,
  title={High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate},
  author={Aaron R Chidakel and S Zweig and Jonathan R Schlosser and Peter John Homel and Joseph Schappert and Adrienne M. Fleckman},
  journal={Journal of Endocrinological Investigation},
  year={2006},
  volume={29},
  pages={136-140}
}
Introduction: Megestrol acetate (MA) is a progestational agent used for palliation of breast and endometrial cancer. The drug promotes weight gain via appetite stimulation. This property has led to widespread use in patients with wasting illnesses. Increasing numbers of reports suggest glucocorticoid activity. Objective: Unrecognized adrenal suppression may result from MA use. This is the first study to examine the prevalence of adrenal suppression in hospitalized patients treated with MA… 
Megestrol acetate-associated adrenal insufficiency.
TLDR
This case of adrenal insufficiency in an elderly woman with worsening dyspnea was probably related to MA use and Clinicians should be alert to the possibility of this adverse effect when considering use of MA therapy.
Megace Mystery: A Case of Central Adrenal Insufficiency
TLDR
A patient who presented with clinical and biochemical features of central adrenal insufficiency was described, and the use of an exogenous glucocorticoid was suspected but was initially denied by the patient; ultimately, the culprit medication was uncovered when a synthetic steroid screen revealed the presence of MA.
Secondary Adrenal Insufficiency Associated with Megestrol Acetate in a Patient with Lung Cancer
TLDR
A case of secondary adrenal insufficiency associated with megestrol acetate in a patient with lung cancer is presented and awareness of the glucocorticoid-like activity of megestro acetate and its side effects are important for the diagnosis of adrenal Insufficiency.
Megestrol acetate improves weight gain in pediatric patients with chronic kidney disease.
TLDR
MA appears to effectively improve weight gain in pediatric CKD patients with minimal adverse side effects and may therefore serve as a safe, short-term, nutritional strategy.
Megestrol Acetate and Mirtazapine for the Treatment of Unplanned Weight Loss in the Elderly
TLDR
Megestrol acetate and mirtazapine appear to be effective for appetite stimulation and weight gain in some settings, however, applicability of the data to elderly individuals is unclear, and adverse events reported in a few of the trials and in case reports were not benign.
Safety and Efficacy of Two Preparations of Megestrol Acetate in HIV-Infected Individuals with Weight Loss in Africa, India, and the United States
TLDR
The efficacy and safety of a new formulation of megestrol acetate concentrated suspension was compared with traditional megestro acetate oral sus- pension in 63 HIV-infected adults with weight loss in South Africa, India, and the United States.
Endocrinopathy of the Critically Ill
TLDR
Combined administration of hypothalamic releasing factors has shown to reactivate the neuroendocrine axes, and whether this intervention is able to improve short-term recovery, as well as long-term rehabilitation, needs thorough investigation in appropriately designed, adequately powered randomized controlled clinical trials.
The risk of pill cutter sharing.
TLDR
The ase of a patient with secondary adrenal insufficiency due to sing the same pill cutter for her medications and her dog’s rednisone is described, who is shown to be secondary to ACTH suppression.
Decompensated septic shock in the setting of megace-induced severe adrenal suppression in an otherwise healthy pediatric patient: a case report.
TLDR
This is the first report of this adverse effect of Megace in suppressing adrenal function in patients with cancer and acquired immunodeficiency syndrome in an otherwise healthy child.
Adrenal function in cystic fibrosis.
TLDR
Practical guidelines regarding the screening, diagnosis, and treatment of iatrogenic adrenal insufficiency are provided and the need for studies to evaluate the impact of CF therapies on adrenal function and other CF-endocrinopathies is highlighted.
...
1
2
3
...

References

SHOWING 1-10 OF 25 REFERENCES
Induction of Adrenal Suppression by Megestrol Acetate in Patients with AIDS
TLDR
A patient with AIDS in whom megestrol acetate appeared to have induced adrenal insufficiency was observed, and the glucocorticoid activity of this drug was investigated.
Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients.
TLDR
Increase in weight during the early stages of megestrol acetate therapy is related to the extent of in vivo drug exposure above a threshold concentration, according to a statistically significant correlation between the ratio of body weight at 3 weeks/initial weight (weight index) and the percentage of the 24-h dosing interval that megestro acetate concentrations exceeded a 300-ng/ml threshold.
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
TLDR
A positive dose-response effect for megestrol acetate on appetite stimulation supports both the prestudy hypothesis and other available literature and it is reasonable to use 160 mg/d for the initial treatment of cancer anorexia/cachexia in routine clinical practice.
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
TLDR
This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.
Megestrol Acetate in Patients with AIDS-related Cachexia
TLDR
This multicenter, double-blind, placebo-controlled study was designed to assess the safety and efficacy of megestrol acetate for the treatment of AIDS-related anorexia and cachexia in patients with AIDS-associated weight loss.
Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.
TLDR
Clinicians need to be aware of this association as therapy with megestrol can result in clinical manifestations of glucocorticoidlike activity, including Cushing syndrome, diabetes, and adrenal insufficiency, as these complications can be life-threatening if not recognized.
Effect of megestrol acetate on the human pituitary-adrenal axis.
TLDR
The data from these evaluations demonstrate that megestrol acetate reversibly decreases serum cortisol concentrations in humans and that this effect seems to originate from a suppression of the pituitary-adrenal axis.
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
TLDR
Whereas fluoxymesterone clearly seems to be an inferior choice for treating cancer anorexia/cachexia, megestrol acetate and dexamethasone have similar appetite stimulating efficacy but differing toxicity profiles.
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
TLDR
The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer.
Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
TLDR
It is indicated that MA causes profound suppression of adrenal steroid production but in addition suppresses ovarian secretion of androgens in postmenopausal breast cancer patients and is responsible for its antitumor effects in breast cancer.
...
1
2
3
...